Featured Video Play Icon

Thanks for visiting us at CPhI 2022 in Frankfurt!

CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very successful days full of exciting meetings and inspiring discussions. It was a great pleasure to present TIEFENBACHER GROUP´s latest ideas to make pharmaceuticals more affordable, more available, and better than before.  

Thanks a lot for visiting us at our new booth representing TIEFENBACHER GROUP as a global health pioneer. We are already looking forward to seeing you next year in Barcelona at CPhI 2023! 

You couldn’t come to the CPhI? Do not hesitate to contact us via info@aet.eu to learn more about our product portfolio and innovative health care solutions – or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963 

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before. 


Featured Video Play Icon

TIEFENBACHER GROUP opens new manufacturing site in Cyprus

Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously opened in mid-October. The “Delorbis” plant is one of the most modern pharmaceutical production site in the European Union. Its facilities are equipped with state-of-the art technologies for the manufacturing of oral dosage forms. This investment follows TIEFENBACHER GROUP´s strategy to strengthen its position as a global, fully integrated pharmaceutical company.

Check out our short video and get an impression of the festive inauguration of the new plant!

For further information about our portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®

TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.

TIEFENBACHER GROUP and OnDosis today announced the launch of the OYSTA® brand. OYSTA® represents the extensive co-development portfolio of drug/device combinations that was initiated in September 2020 and covers several indications such as ADHD, Parkinson´s disease, transplantation, and pain medicines as well as rare pulmonary diseases. The first product, combining a stimulant with the proprietary dosage manager for patients with ADHD, is already planned for launch in the US in 2024. Other indications will stand in line as next wave developments.

OYSTA® captures the essence of the value proposition of the products under development: a safe “shell” (proprietary dosage manager) to protect medicines formulated as “pearls” (pellets or granules) to allow for intuitive, flexible, and precise dosing.

Through the OYSTA® collaboration, OnDosis will benefit from a partner with leading competence in pharmaceutical development, supply chain, and B2B commercialization, whilst TIEFENBACHER GROUP gets access to an innovative product concept with game-changing potential in the new era of individualization of treatments and digitalization in healthcare.

“OYSTA® allows us to clearly position the products we are co-developing in conversation with commercialization partners as well as with health care professionals and end users. It is ultimately a sign that our common efforts to bring innovation to patients is getting closer to market” says Kristian Ruepp, Managing Director at TIEFENBACHER GROUP.

“OYSTA® perfectly captures the essence of what we want to achieve together in this exciting collaboration: individualized dosing of solid oral medicines formulated as “pearls” and protected within a device “shell” which gives reassurance to patients, caregivers, and healthcare professionals.  Under one name, we are co-developing a portfolio of innovative products as one team, with the ambition to revolutionize how patients take their medicines. That revolution is now accelerating” says Martin Olovsson, CEO at OnDosis.

TIEFENBACHER GROUP and OnDosis will first present the OYSTA® brand in public at CPhI 2022 in Frankfurt (Nov 1-3). To schedule a meeting please contact TIEFENBACHER GROUP via info@aet.eu.

About TIEFENBACHER GROUP

100% family owned since 1963 TIEFENBACHER GROUP is a global health care company providing innovative and best-in-class solutions along the entire pharmaceutical value chain. That includes the distribution of API ́s and the development, manufacturing, and registration of finished dosage forms. The world ́s most trusted health care brands count on TIEFENBACHER’s pioneer spirit as well as its pharmaceutical excellence. Leveraging its global presence including own laboratories and manufacturing sites, TIEFENBACHER is driven to make pharmaceuticals more affordable, more available, and better than before. There is one purpose driving TIEFENBACHER’s about 800 employees day by day: improving the life of millions of patients worldwide. www.tiefenbachergroup.com

About OnDosis

A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage — individualized, intuitive, and intelligent — in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. www.ondosis.com

For any request regarding a collaboration in one of the five indications mentioned above, please contact TIEFENBACHER GROUP. For interest in any other indication or solely the device please contact OnDosis:

Dr. Kristian Ruepp
Joint Managing Director, TIEFENBACHER GROUP

Tel: +49 40 – 44 18 09-0; info@aet.eu

Martin Olovsson
CEO, OnDosis

Tel: +46 76 772 85 01; m.olovsson@ondosis.com

OYSTA® is a registered trademark jointly owned by TIEFENBACHER GROUP and OnDosis. The OYSTA® products are co-developed based in the proprietary dosage manager device platform developed by OnDosis.


Meet TIEFENBACHER GROUP at CPhI in Frankfurt from 1-3 Nov and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!

We are very excited to meet our valued customers and partners once again on CPhI 2022, the world´s leading pharma industry event! 

Explore our new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations in the field of raw materials, finished dosage forms, and medical devices! Get in touch with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide! 

CPhI 2022 will take place on November 1-3 at Messe Frankfurt, Germany. We’ll be happy to meet you at our stand 80B70 at any time during the event. The arrangement of prescheduled meetings is highly appreciated. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu. 

TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on www.tiefenbachergroup.com 


Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees

From racing bikes to E-bikes: since this year all our employees at our Hamburg headquarters can choose from a broad range of company bikes to lease. A great opportunity for everyone to stay fit and healthy and fully aligned with TIEFENBACHER GROUP´s strategy of doing business sustainable! As with car leasing, the monthly instalment is deducted from the monthly gross salary through salary conversion.

We are very optimistic to reach soon our target that at least 30% of our Hamburg employees will cycle to work instead of taking their car. One step further on our way to less CO2 emissions!  And of course, we have sufficient bicycle parking spaces in our underground garage – including numerous electric charging station for electric vehicles.

For further information about our corporate social responsibility activities and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)

We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a non-profit business membership organization striving for better social, health, safety, and environmental outcomes in pharmaceutical supply chains. It follows our company´s strategy to make medicines better affordable, better available, and better than before in a sustainable way – better for people and the planet!

PSCI is a group of international pharmaceutical and healthcare companies who share together the vision of responsible supply chains. The organization was founded in 2006 and is legally established in the United States. Today PSCI already counts 63 members. For more information about the organization have a look at: PSCI (pscinitiative.org) .

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA

TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for TIEFENBACHER GROUP to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.

The lab is equipped with the latest techniques with full safety protection measurements and will be extended by an additional manufacturing block with special technologies in 2023. The new complex will cover a total of about 4.000 square meters.

TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in the new facilities in Hyderabad. While the operational start of the lab (including small-scale production) is planned for this year, the commercial production for larger quantities in the new manufacturing block is expected for 2024.

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


WORLD HEALTH DAY @ TIEFENBACHER GROUP

Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since 1963 we at TIEFENBACHER GROUP are pioneering healthcare to improve patients´ lives around the world. Today we serve over 500 million patients every year with our pharmaceutical products and innovative healthcare solutions. In everything we do we are led by three questions: are we making high-quality pharmaceuticals better affordable, better globally available, or better than before?

For information about our product portfolio and innovative healthcare solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve
patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!

One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP presenting our latest product portfolio and innovations to our existing and potential new partners. Check out our short video to get some impressions!

For further information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP STANDS WITH UKRAINE

To us at TIEFENBACHER GROUP, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign country. Our thoughts are with everyone affected by this war. We stand with all Ukrainians and have already donated urgently needed medicine to a hospital in Kyiv and are currently checking further supply options. To support emergency aid for children and families in Ukraine we have also made a significant monetary donation to UNICEF.

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com